FY2018 EPS Estimates for Chembio Diagnostics, Inc. (CEMI) Lifted by Analyst
Chembio Diagnostics, Inc. (NASDAQ:CEMI) – Equities research analysts at Zacks Investment Research lifted their FY2018 earnings per share estimates for Chembio Diagnostics in a research report issued on Wednesday. Zacks Investment Research analyst B. Marckx now expects that the company will post earnings per share of ($0.23) for the year, up from their prior estimate of ($0.27). Zacks Investment Research also issued estimates for Chembio Diagnostics’ FY2019 earnings at ($0.11) EPS.
Shares of Chembio Diagnostics (NASDAQ CEMI) traded up $0.25 during mid-day trading on Monday, reaching $7.30. The company’s stock had a trading volume of 8,828 shares, compared to its average volume of 21,072. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.54 and a quick ratio of 2.19. Chembio Diagnostics has a 52-week low of $5.05 and a 52-week high of $7.60.
WARNING: “FY2018 EPS Estimates for Chembio Diagnostics, Inc. (CEMI) Lifted by Analyst” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/12/13/fy2018-eps-estimates-for-chembio-diagnostics-inc-cemi-lifted-by-analyst.html.
Chembio Diagnostics Company Profile
Chembio Diagnostics, Inc (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc, develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company’s products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies.
Receive News & Ratings for Chembio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chembio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.